A Novel Homozygous Intronic Variant in TNNT2 Associates With Feline Cardiomyopathy

James W. McNamara1*, Maggie Schuckman2, Richard C. Becker1 and Sakthivel Sadayappan1**

1 Division of Cardiovascular Health and Disease, Department of Internal Medicine, Heart, Lung and Vascular Institute, University of Cincinnati, Cincinnati, OH, United States, 2 Department of Cardiology, MedVet Cincinnati, Fairfax, OH, United States

Background: Hypertrophic cardiomyopathy (HCM) is a genetic disease of the heart and the most common cause of sudden cardiac death in the young. HCM is considered a disease of the sarcomere owing to the large number of mutations in genes encoding sarcomeric proteins. The riddle lies in discovering how these mutations lead to disease. As a result, treatments to prevent and/or treat HCM are limited to invasive surgical myectomies or ablations. The A31P variant of cardiac myosin binding protein-C, encoded by MYBPC3, was found to be more prevalent in a cohort of Maine Coon cats with HCM. However, other mutations in MYBPC3 and MYH7 have also been associated with HCM in cats of other breeds. In this study, we expand the spectrum of genes associated with HCM in cats.

Results: Next Generation Whole Genome sequencing was performed using DNA isolated from peripheral blood of a Maine Coon with cardiomyopathy that tested negative for the MYBPC3 A31P variant. Through risk stratification of variants, we identified a novel, homozygous intronic variant in cardiac troponin T (TNNT2). In silico analysis of the variant suggested that it may affect normal splicing of exon 3 of TNNT2. Both parents tested heterozygous for the mutation, but were unaffected by the disease. Echocardiography analyses revealed that the proband had shown early onset congestive heart failure, which is managed with a treatment regime including ACE and aldosterone inhibitors.

Conclusion: In summary, we are the first to demonstrate the association between TNNT2 mutations and HCM in felines, suggesting that this gene should be included in the testing panel of genes when performing genetic testing for HCM in cats.

Keywords: Hypertrophic Cardiomyopathy, Maine Coon, MYBPC3, TNNT2, sarcomere

INTRODUCTION

Hypertrophic cardiomyopathy (HCM) is the most common form of genetic heart disease, affecting at least 1 in 500 humans (Ho, 2011). Defined by an unexplained abnormal thickening of the ventricular walls and possible outflow tract obstruction, no cure is currently available for HCM. HCM is primarily caused by mutations in genes that encode sarcomeric proteins. In particular,
mutations in MYH7 and MYBP3, encoding beta-cardiac myosin heavy chain and cardiac myosin binding protein-C, respectively, are the most commonly mutated genes (Viswanathan et al., 2017), although other sarcomeric genes, including TNNI3, TNNT2, and MYL2, have also been implicated in humans (Brouwer et al., 2011). How mutations in these sarcomeric genes result in the development of HCM remains poorly understood.

In cats, cardiomyopathy is the main cause of cardiovascular disease, with HCM presenting as the most common form, suggesting that cats may be an excellent non-rodent animal model of HCM (Ferasin et al., 2003). A variant in MYBP3, A31P, was previously linked to the development of HCM in Maine Coon cats (Meurs et al., 2005). This variant occurs within the C0 domain of cardiac myosin binding protein-C (cMyBP-C), and it is expected to cause disease via structural defects in this domain important for regulation of actomyosin regulation (Van Dijk et al., 2016). Another variant in MYBP3, A74T, has also been described across multiple cat breeds. However, in-depth follow-up studies demonstrated that this polymorphism is unrelated to cardiomyopathy (Wess et al., 2010; Longeri et al., 2013). A third variant in MYBP3, R820W, has been associated with HCM, most specifically in the Ragdoll (Meurs et al., 2007). More recently, the first variant in MYH7, E1883K, has been associated with HCM in a Domestic Shorthair cat, expanding the spectrum of genes associated with feline cardiomyopathy (Schipper et al., 2019). A full list of mutations associated with feline cardiomyopathy is shown in Table 1.

In the present study, a male Maine Coon cat with cardiomyopathy and early congestive heart failure was studied. After initially screening negative for the aforementioned A31P mutation, we performed WGS to identify potential mutations and, thus, pinpoint the genetic cause of this cat's cardiomyopathy through study of the diseased cat's family tree. This study expands upon recent Next Generation Sequencing performed in cats (Genova et al., 2018; Ontiveros et al., 2018). As a result, we have identified a novel autosomal recessive mutation in the sarcomeric cardiac troponin T (TNNT2) gene that appeared to be associated with feline cardiomyopathy. This is the first known record of such mutation in felines, suggesting that TNNT2 should be included as a candidate gene in the genetic screenings.

**MATERIALS AND METHODS**

**Phenotyping, Blood Collection and DNA Extraction**

All procedures followed the protocol approved by the Institutional Animal Care and Use Committee of the University of Cincinnati and complied with the Guide for the Use and Care of Laboratory Animals published by the National Institutes of Health. The proband’s owner established contact to determine if the animal’s disease could be linked to a genetic mutation. To establish a full research study, a Material Transfer Agreement was initiated between the proband’s owner and the University of Cincinnati. Researchers had no contact with any animals beyond receipt of blood samples. All studies involving contact with animals were performed by board certified veterinarians. Diagnosis and treatment of the proband, regular checkups and echocardiography were performed by a board certified veterinary cardiologist using standard echocardiographic techniques and references from a population of healthy Maine Coon cats (Thomas et al., 1993; Drourr et al., 2005). Peripheral blood was collected by a certified veterinarian or veterinarian nurse at each animal’s local hospital following a routine check-up. Blood collected locally was transported back to the laboratory on wet ice. Blood that was collected at veterinary clinics farther from the lab was shipped on cold blocks overnight. Upon receipt at the laboratory, all blood samples were aliquoted into 200 µl samples and stored at −80°C until use. DNA was extracted from a single 200 µl aliquot using the Qiagen QIAamp DNA Mini and Blood DNA isolation kit, following the manufacturer’s protocol.

**Whole Genome Sequencing and Analysis**

DNA extracted from the whole blood of the proband was submitted to Novogene Co., Ltd., for WGS. DNA quality and quantity were confirmed by Agarose gel electrophoresis and Qubit Fluorometer. A total amount of 1.5 µg high-quality genomic DNA was randomly sheared into short fragments of approximately 350 bp and used for library construction using the NEBNext® DNA Library Prep Kit. Briefly, following end repairing, dA-tailing, and ligation with NEBNext adapter, the fragments were PCR-enriched by P5 and indexed P7 oligos. The concentration of the DNA library was quantified using the Qubit 2.0 fluorometer and diluted to 1 ng/µl. Following dilution, the insert size of the library was assessed with the Agilent 2100 bioanalyzer and concentration and purity of DNA was analyzed by NanoDrop. Samples for sequencing were sent to Novogene, DNA integrity and concentration were also determined using the Agilent 2100 Bioanalyzer and Qubit Fluorometer, respectively.

| Gene | Mutation | Breed | References |
|------|----------|-------|------------|
| MYBPC3 | A31P | Maine Coon | Meurs et al. (2005) |
| MYBPC3 | R820W | Ragdoll | Meurs et al. (2007) |
| MYH7 | E1883K | Domestic Shorthair | Schipper et al. (2019) |

**Bioinformatics Analysis**

The original sequencing data acquired by high-throughput sequencing platforms (e.g., Illumina HiSeq™/NovaSeq™) and recorded in image files were first transformed to sequence reads by base calling with the CASAVA software. Information on sequences and corresponding sequencing quality was stored in a FASTQ file. Following quality control of raw sequencing data for clean data filtration, each clean read was mapped to the reference genome (Felis_Catus_9.0, Ensembl release 93) using the BWA software (Li and Durbin, 2009), and the mapping
rate and coverage were counted according to the alignment results. Duplicates were removed by SAMTOOLS (Li et al., 2009). Single nucleotide polymorphism (SNP) and InDel variants were detected using the GATK software (Depristo et al., 2011). These SNPs were annotated using ANNOVAR as previously described (Wang et al., 2010).

Sanger Sequencing
To test, or confirm, the presence of a genetic variant in parents of the proband, PCR was performed using a high-fidelity Taq polymerase to specifically amplify the sequence around the variant. The PCR product was purified and sent for Sanger sequencing using Cincinnati Children’s Hospital DNA Sequencing and Genotyping Core Facility.

RESULTS
The proband was a privately-owned male pure-bred Maine Coon. At 8 months of age, he presented with left ventricular, right atrial, and borderline left atrial dilatation and borderline septal hypertrophy, with preserved-to-elevated systolic function (Figures 1A,B and Table 2), when compared to reference echocardiography values for the Maine Coon (Drourr et al., 2005). Diastolic function could not be quantified as a result of fusion of E and A waves. Progressive enlargement of all four chambers of the heart was noted at 14 months of age, while borderline septal hypertrophy and preserved systolic function was still noted. This was diagnosed as a primary unclassified cardiomyopathy with possible early congestive heart failure. Furosemide, Benazepril, Spironolactone, and Clopidogrel treatments were then initiated by the veterinarian. This combination appeared to stabilize the progression of the heart disease at 18 months (Table 2).

DNA was isolated from whole peripheral blood from the proband. PCR was performed to produce a 251 amplicon around the A31P variant in MYBPC3 previously associated with HCM in Maine Coon cats (primer sequences in Table 3). Sanger sequencing of the PCR product showed no mutation at codon 31, indicating that the proband did not carry the pathogenic A31P variant in MYBPC3 (Figure 1C).

As the proband was negative for the A31P mutation in MYBPC3, we asked if any other variants could be traced to the proband’s cardiomyopathy. Accordingly, DNA was freshly isolated for WGS to identify potential variants present in the proband. High-quality DNA with an approximate size of 22944bp

| TABLE 2 | Echocardiography parameters from serial measurements performed by a board-certified veterinary cardiologist. |
| Parameter | Proband | References |
|---|---|---|
| Age (month) | 10 | 14 | 18 | 24 | ≥12 |
| IVSd (mm) | 6 | 5.9 | 5.8 | 5.94 | 3.9–4.1 |
| LVIDd (mm) | 19.3 | 19.9 | 21.8 | 21.7 | 18.1–18.9 |
| LVPWd (mm) | 5.1 | 5.5 | 5.2 | 5.55 | 4.2–4.4 |
| IVSs (mm) | 9.6 | 9.2 | N/A | N/A | 7.2–7.8 |
| LVIDs (mm) | 9 | 9.6 | 7.7 | 8.1 | 8.5–9.3 |
| LVPWs (mm) | 9.6 | 9.4 | N/A | N/A | 7.8–8.2 |
| %FS | 60.6 | 59.5 | 64.2 | 62.6 | 50.35–53.35 |
| LA (mm) | 17.6 | 19.8 | 18.9 | 19.7 | 13.4–14.0 |
| LA/Ao | 1.33 | 1.58 | 1.53 | 1.44 | 1.20–1.26 |

Significant dilatation of all cardiac chambers was noted with normal to elevated systolic function. Treatments administered are listed. IVS, interventricular septal thickness; LVID, left ventricular internal diameter; LVPW, left ventricular posterior wall thickness; FS, fractional shortening; LA, left atrial dimension; LA/Ao Left atrium-to-aortic root ratio; d, diastole; s, systole. N/A represents data not available.

FIGURE 1 | Cardiomyopathy in the absence of the MYBPC3 A31P variant. (A,B). Representative echocardiography and outline of cardiovascular disease risk stratification of genetic variants. Representative parasternal long axis B-Mode (A) and M-Mode (B) images of proband, with left ventricle (LV), left atrium (LA) and right ventricle (RV) labeled. (C). Chromatogram of MYBPC3 A31P demonstrated that the proband was negative for this variant.
TABLE 3 | List of primer sequences used in this study to test for the presence of variants in MYBPC3 and TNNT2 genes.

| Primer name    | Primer sequence                        | Amplicon size (bp) |
|---------------|----------------------------------------|--------------------|
| Cat_A31P_F    | AGTCTCAGCTTCAGGAAAGGCG                 | 252 bp             |
| Cat_A31P_R    | GGTCAAACTTGACCTGGAGGAGGCG              |                    |
| Cat_TNNT2_F   | TGAGTGATGTGGCTGTGGTT                   | 287 bp             |

was sent for library preparation and sequencing by Novogene. Sequences were aligned against the Felis Catus reference genome (Ensemble release 93). The sequencing resulted in 177,419,470 raw reads, with an average depth of 17.59 reads per base, an error rate of 0.03, and 94.19% of base reads with a Phred score greater than 30 (Figures 2A–C). The detected GC content was 43.06% compared to the reference genome of 41.73%. Together, these data demonstrated sufficiently high quality of sequencing data.

Initial analysis reported more than 20,000 genetic variants identified from the proband, compared to the reference genome. We employed a cardiovascular disease risk stratification step in order to enrich for variants associated with cardiovascular disease. This stratification was with 174 genes covered by the Illumina TruSight Cardio Panel (Pua et al., 2016). This approach reduced the number of variants to 305 (Figure 2D). Of these 305 potential variants, only one had been annotated as having “high risk” impact. This particular variant was a single base pair substitution (G to A) within intron 3, corresponding to c.95-108G > A of ENSFCAG00000004613. This variant resulted in the potential inclusion of a de novo splice acceptor site (Figure 3A). We then used in silico analysis to determine the likelihood that this intronic variant indeed acts as a novel splice acceptor site (Wang and Marin, 2006). This in silico method correctly identified greater than 96% of canonical splice donors and acceptors within TNNT2 (Table 4). Of note, in silico analysis of the c.95-108G > A variant in the proband supported...
the hypothesis that this variant alters TNNT2 splicing. The consequence of this aberrant splicing was investigated at the protein level, which revealed that the variant could cause the loss of 223 carboxyl terminal amino acids and incorporation of only five novel amino acids, rendering the protein non-functional (Figure 3B).

Sanger sequencing was performed to validate the WGS annotation of the c.95-108G > A variant in the proband (primer sequence in Table 3). Strikingly, this sequencing revealed homozygosity of the c.95-108G > A variant in the proband, further suggesting its disease association (Figure 3C). Following this finding, blood samples from both parents of the proband were obtained. Echocardiography did not suggest any cardiac pathology in either of these parents (data not shown). DNA was extracted and PCR performed for Sanger sequencing of the TNNT2 variant. Strikingly, both parents harbored a single copy of the c.95-108G > A variant (Figure 3C). This finding led to investigations into the pedigree of the proband. It was found that the proband was born from consanguineous breeding (Figure 4). Taken together, these results implicate a novel intronic mutation which results in the truncation of the sarcomeric protein, cardiac troponin T, as the cause of cardiomyopathy in this Maine Coon cat.

### DISCUSSION

In this study, we identified a novel homozygous intronic variant in TNNT2 which was associated with a case of feline cardiomyopathy and early heart failure. Mutations in MYBPC3 and MYH7 have previously been described. However, to the best of our knowledge, this is the first report of a thin filament mutation associated with feline cardiomyopathy (Meurs et al., 2005; Schipper et al., 2019). Mutations in TNNT2 have been strongly implicated in the development of HCM and dilated cardiomyopathy (Watkins et al., 1995; Pasquale et al., 2012). In humans, these TNNT2 mutations are described as phenotypically mild compared to MYH7 mutations, but with a higher incidence of sudden cardiac death (Watkins et al., 1995). Importantly, mutations in intronic splice sites have been identified as causative of cardiomyopathy in humans (Thierfelder et al., 1994). Taken together, these data support our finding that the TNNT2 intronic mutation we describe is the most likely cause of this case of feline cardiomyopathy.

The TNNT2 gene encodes the cardiac-specific sarcomeric protein cardiac troponin-T (cTnT) (Wei and Jin, 2016). Cardiac troponin-C and -I (cTnC and cTnI, respectively), together with cTnT, make up the troponin complex of the heart (Gomes et al., 2002). The troponin complex is associated with the thin filaments, and cTnT is understood to play an important role in anchoring the complex to both actin and tropomyosin (Gomes et al., 2002). When calcium is released from the sarcoplasmic reticulum, it binds to and induces a structural change in cTnC (Vinogradova et al., 2005), ultimately leading to the movement of tropomyosin, allowing the formation of cross-bridges (Boussouf et al., 2007). cTnT has been demonstrated to regulate the calcium

---

**TABLE 4** In silico prediction of exon splicing sites of cat TNNT2 (ENSCFA0000004613) gene.

| Position | Predicted Splice | Score | Confidence |
|----------|------------------|-------|------------|
| Exon 1 Donor | Constitutive donor | 11.931 | 0.332 |
| Exon 2 Acceptor | Alt. isoform/cryptic acceptor | 5.476 | 0.495 |
| Exon 2 Donor | Constitutive donor | 11.4 | 0.405 |
| Exon 3 de novo Acceptor | Constitutive acceptor | 4.688 | 0.396 |
| Exon 3 Acceptor | Alt. isoform/cryptic acceptor | 6.649 | 0.509 |
| Exon 3 Donor | Constitutive donor | 13.878 | 0.871 |
| Exon 4 Acceptor | Constitutive acceptor | 5.828 | 0.568 |
| Exon 4 Donor | Constitutive donor | 15.502 | 0.523 |
| Exon 5 Acceptor | Constitutive acceptor | 12.683 | 0.888 |
| Exon 5 Donor | Constitutive donor | 15.343 | 0.801 |
| Exon 6 Acceptor | Constitutive acceptor | 10.572 | 0.727 |
| Exon 6 Donor | Alt. isoform/cryptic donor | 10.982 | 0.805 |
| Exon 7 Acceptor | Constitutive acceptor | 8.308 | 0.85 |
| Exon 7 Donor | Alt. isoform/cryptic donor | 8.771 | 0.782 |
| Exon 8 Acceptor | Constitutive acceptor | 10.214 | 0.924 |
| Exon 8 Donor | Constitutive donor | 13.02 | 0.872 |
| Exon 9 Acceptor | Not Predicted | N/A | N/A |
| Exon 9 Donor | Alt. isoform/cryptic donor | 11.345 | 0.347 |
| Exon 10 Acceptor | Constitutive acceptor | 8.201 | 0.438 |
| Exon 10 Donor | Constitutive donor | 11.746 | 0.511 |
| Exon 11 Acceptor | Constitutive acceptor | 8.577 | 0.643 |
| Exon 11 Donor | Alt. isoform/cryptic donor | 10.946 | 0.235 |
| Exon 12 Acceptor | Constitutive acceptor | 8.91 | 0.812 |
| Exon 12 Donor | Constitutive donor | 8.271 | 0.728 |
| Exon 13 Acceptor | Constitutive acceptor | 11.353 | 0.443 |
| Exon 13 Donor | Constitutive donor | 12.265 | 0.581 |
| Exon 14 Acceptor | Constitutive acceptor | 10.067 | 0.841 |
The sequencing data has been deposited into the BioProject database (accession: PRJNA671288).

ETHICS STATEMENT

The animal study was reviewed and approved by Ref: AM07-19-10-03-01 Institutional Animal Care and Use Committee OLAW Assurance D16-00190, AAALAC 00278 University of Cincinnati PO Box 210572, Cincinnati, OH 45267-0572. Written informed consent was obtained from the owner for the participation of their animals in this study.

AUTHOR CONTRIBUTIONS

JM and SS designed the research and wrote the manuscript. JM and MS performed the research. JM, MS, and SS analyzed data. MS and RB edited the manuscript. RB provided project oversight for clinical data. All authors read and approved the final manuscript.

FUNDING

Whole genome sequencing of the proband was funded by a donation from Kathleen and Michael Janson, owners of the proband. JM was supported by an American Heart Association Postdoctoral Fellowship (17POST33630095). SS received funding from the following grants: National Institutes of Health grants R01 AR078001, R01 HL130356, R56 HL139680, R01 AR067279, R01 HL105826, and R01 HL143490; and transformation (19TPA34830084) awards; and MyoKardia, AstraZeneca, Merck, and Amgen.

CONCLUSION

We have identified a novel, homozygous mutation in the sarcomeric gene TNNT2, which is associated with cardiomyopathy in a Maine Coon cat. The homozygosity of this mutation resulted from inbreeding. This study is the first to describe a mutation in TNNT2 that is associated with feline cardiomyopathy, suggesting that this gene should be included in routine genetic testing in felines. Additionally, breeders should be mindful of the dangers associated with close generational consanguineous breeding.

ACKNOWLEDGMENTS

We would like to thank the staff at Warm Animal, Cincinnati; Big Creek, Cleveland; and Friendship, Washington DC veterinary hospitals for performing the blood draws. We also thank Linda Komar and Joseph Keyerleber for organizing the shipments of the proband's parents' blood. Sanger sequencing was performed by Cincinnati Children's Hospital DNA Sequencing and Genotyping Core. This manuscript has been released as a pre-print at Research Square (McNamara et al., 2020).

REFERENCES

Ahmad, F., Banerjee, S. K., Lage, M. L., Huang, X. N., Smith, S. H., Saba, S., et al. (2008). The role of cardiac troponin T quantity and function in cardiac development and dilated cardiomyopathy. PLoS One 3:e2642. doi: 10.1371/journal.pone.0002642

Ahmad, F., Banerjee, S. K., Lage, M. L., Huang, X. N., Smith, S. H., Saba, S., et al. (2008). The role of cardiac troponin T quantity and function in cardiac development and dilated cardiomyopathy. PLoS One 3:e2642. doi: 10.1371/journal.pone.0002642
Brouwer, W. P., Van Dijk, S. J., Stienen, G. J., Van Rossum, A. C., Van Der Velden, J., and Germans, T. (2011). The development of familial hypertrophic cardiomyopathy: from mutation to bedside. Eur. J. Clin. Invest. 41, 568–578. doi: 10.1111/j.1365-2362.2010.04239.x

Depristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C., et al. (2011). A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498.

Droux, L., Lefebre, B. K., Rosenthal, S. L., and Tyrrrell, W. D. J. (2005). Measurement of M-mode echocardiographic parameters in healthy adult Maine Coon cats. J. Am. Vet. Med. Assoc. 226, 734–737. doi: 10.2460/javma.2005.226.734

Ferasin, L., Sturgess, C. P., Cannon, M. J., Caney, S. M., Gruffydd-Jones, T. J., and Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760. doi: 10.1093/bioinformatics/btp324

Gomes, A. V., Liang, J., and Potter, J. D. (2005). Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development. J. Biol. Chem. 280, 30909–30915. doi: 10.1074/jbc.m502872200

Gomes, A. V., Potter, J. D., and Sazzesna-Cordary, D. (2002). The role of troponins in muscle contraction. IUBMB Life 54, 323–333. doi: 10.1080/1521654021603793

Ho, C. Y. (2011). New paradigms in hypertrophic cardiomyopathy: insights from genetics. Prog. Pediatr. Cardiol. 31, 93–98. doi: 10.1016/j.ppedcard.2011.02.005

Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1745–1760. doi: 10.1093/bioinformatics/btp324

McNamara, E. S., Ueda, Y., Harris, S. P., and Stern, J. A. (2018). Precision medicine validation: identifying the MYBPC3 A31P variant with whole-genome sequencing in two Maine Coon cats with hypertrophic cardiomyopathy. J. Vet. Intern. Med. 32, 428–434. doi: 10.1111/jvim.15251

Meurs, K. M., Norgard, M. M., Ederer, M. M., Hendrix, K. P., and Kittleson, M. D. (2007). A substitution mutation in the myosin binding protein C gene in ragdoll Shorthair cat. J. Feline Med. Surg. 9, 252–259. doi: 10.1016/j.jfms.2006.04.006

Nishii, K., Morimoto, S., Minakami, R., Miyano, Y., Hashizume, K., Ohta, M., et al. (2018). Hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77, 701–712. doi: 10.1016/j.cell.2018.05.018

Van Dijk, S. J., Bezdol Kooker, K., Mazzalupo, S., Yang, Y., Kostyukova, A. S., Mustacich, D. J., et al. (2016). The A31P missense mutation in cardiac myosin binding protein C alters protein structure but does not cause haploinsufficiency. Arch. Biochem. Biophys. 601, 133–140. doi: 10.1016/j.abb.2016.01.006

Vinogradova, M. V., Stone, D. B., Malanina, G. G., Karatzafiri, C., Cooke, R., Mendelson, R. A., et al. (2005). Ca(2+)-regulated structural changes in troponin. Nat. Protoc. Sci. Technol. U.S.A. 102, 5038–5043. doi: 10.1037/pnas.0408882102

Wei, B., and Jin, J. P. (2016). TNNT1, TNNT2, and TNNT3: Isoform genes, regulation, and structure-function relationships. J. Bioenerg. Biomembr. 48, 219–227. doi: 10.1007/s10807-015-9673-5

B. J. G., et al. (2019). A feline orthologue of the human MYH7 c.5647G→A (p.Glu1883Lys)) variant causes hypertrophic cardiomyopathy in a Domestic Shorthair cat. Eur. J. Hum. Genet. 27, 1724–1730. doi: 10.1038/s41431-019-0431-4

Tardiff, J. C., Factor, S. M., Tompkins, B. D., Hewett, T. E., Palmer, B. M., Moore, R. L., et al. (1998). A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J. Clin. Invest. 101, 2800–2811. doi: 10.1172/jci2389

Thierfelder, L., Watkins, H., Macrae, C., Lamas, R., Mckenna, W., Vosberg, H. P., et al. (1994). Alpha-troponymasin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77, 701–712. doi: 10.1016/0022-2010(94)90054-x

Thomas, W. P., Gaber, C. E., Jacobs, G. J., Kaplan, P. M., Lombard, C. W., Moise, N. S., et al. (1993). Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J. Vet. Intern. Med. 7, 247–252. doi: 10.1172/jvim.1993.1676.1993.b01015

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 McNamara, Schuckman, Becker and Sadayappan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.